Share This Article
GE HealthCare is rolling out a new computed tomography (CT) system to support practitioners in diagnosing complex coronary artery disease (CAD) cases.
The company’s new Revolution Vibe system was formally launched at the American College of Cardiology (ACC) 2025 meeting, taking place in Chicago from 29 to 31 March.
According to GE HealthCare, Vibe, which allows for cardiac CT angiography (CCTA), in which contrast dyes are used to visualise blood vessels to aid in diagnosing advanced cardiovascular diseases (CVD) such as atrial fibrillation and heavily calcified coronaries, is critical at a time where CVD incidence is seeing a dramatic rise worldwide.
CVDs are the leading cause of mortality worldwide, with research forecasting that total coronary and stroke deaths in the US could rise by around 18% – indicative of around 67,000 additional coronary deaths per year – by 2030. Between 2025 and 2050, CVD prevalence is forecast to increase by a staggering 90%.
Jean-Luc Procaccini, president and CEO of molecular imaging and computed tomography at GE HealthCare, commented: “Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population.
